SCHEMBL8937225

SCHEMBL8937225

COc1ccc(C(=CC(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2cc(F)cc(F)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
CYP1A2 P05177 1/20 0.53
PKM P14618 1/20 0.52
POLB P06746 1/20 0.51
GAA P10253 1/20 0.48
GPR183 P32249 1/20 0.47
TP53 P04637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46
TUBA1A Q71U36 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937354 1.00 ALDH1A1 (0.67) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937224 1.00 ALDH1A1 (0.67) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937620 0.92 ALDH1A1 (0.79) ALDH1A1L3MBTL1CYP1A2POLBGAA
SCHEMBL8937302 0.91 ALDH1A1 (0.55) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937299 0.91 ALDH1A1 (0.55) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937542 0.91 ALDH1A1 (0.64) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937535 0.91 ALDH1A1 (0.64) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937437 0.90 PKM (0.62) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937441 0.90 PKM (0.62) ALDH1A1L3MBTL1CYP1A2PKMPOLB
SCHEMBL8937580 0.90 PKM (0.62) ALDH1A1L3MBTL1CYP1A2PKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed